Cargando…

Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept

BACKGROUND: Alterations in the composition of the fecal microbiota in children with juvenile idiopathic arthritis (JIA) have been observed in several studies, but it has not been determined whether the standard treatment for JIA changes the composition or function of the microbiota. The first-line d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Öman, Anders, Dicksved, Johan, Engstrand, Lars, Berntson, Lillemor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077782/ https://www.ncbi.nlm.nih.gov/pubmed/33902613 http://dx.doi.org/10.1186/s12969-021-00542-0

Ejemplares similares

A Pilot Study Investigating Faecal Microbiota After Two Dietary Interventions in Children with Juvenile Idiopathic Arthritis
por: Berntson, Lillemor, et al.
Publicado: (2022)

Gut microbiota-host interactions and juvenile idiopathic arthritis
por: Arvonen, Miika, et al.
Publicado: (2016)

A pilot study of possible anti-inflammatory effects of the specific carbohydrate diet in children with juvenile idiopathic arthritis
por: Berntson, Lillemor
Publicado: (2021)

Haptoglobin in Juvenile Idiopathic Arthritis
por: Berntson, Lillemor, et al.
Publicado: (2022)

Condylar alterations and facial growth in children with juvenile idiopathic arthritis
por: Cedströmer, Anna-Lena, et al.
Publicado: (2020)

Distinct Effects of Methotrexate and Etanercept on the B Cell Compartment in Patients With Juvenile Idiopathic Arthritis
por: Glaesener, Stephanie, et al.
Publicado: (2014)

Ankle arthritis predicts worse outcome in children with juvenile idiopathic arthritis
por: Esbjörnsson, Anna-Clara, et al.
Publicado: (2014)

Susceptibility to Campylobacter Infection Is Associated with the Species Composition of the Human Fecal Microbiota
por: Dicksved, Johan, et al.
Publicado: (2014)

An explorative study on proteomic analyses related to inflammation and pain in children with juvenile idiopathic arthritis
por: Elfving, Andreas, et al.
Publicado: (2023)

Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
por: Levälampi, Tiina, et al.
Publicado: (2023)

No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
por: Schmeling, Heinrike, et al.
Publicado: (2012)

A cross-sectional cohort study of the activity and turnover of neutrophil granulocytes in juvenile idiopathic arthritis
por: Backlund, Malin, et al.
Publicado: (2021)

Challenges in the management of juvenile idiopathic arthritis with etanercept
por: Pain, Clare E, et al.
Publicado: (2009)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

A qualitative evaluation of the specific carbohydrate diet for juvenile idiopathic arthritis based on children’s and parents’ experiences
por: Hagström, Naima, et al.
Publicado: (2023)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Temporomandibular signs, symptoms, joint alterations and disease activity in juvenile idiopathic arthritis – an observational study
por: Cedströmer, Anna-Lena, et al.
Publicado: (2013)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Etanercept treatment in juvenile idiopathic arthritis: The Polish registry
por: Żuber, Zbigniew, et al.
Publicado: (2011)

Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis
por: Maciejewska-Paszek, Izabela, et al.
Publicado: (2017)

Prognostic factors for the disease course and 8-year outcome in Nordic children with oligoarticular-onset juvenile idiopathic arthritis
por: Peltoniemi, Suvi, et al.
Publicado: (2014)

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
por: Khraishi, Majed, et al.
Publicado: (2019)

Clinical remission in juvenile idiopathic arthritis after termination of etanercept
por: Postępski, Jacek, et al.
Publicado: (2012)

Temporomandibular condylar alterations in juvenile idiopathic arthritis most common in longitudinally severe disease despite medical treatment
por: Cedströmer, Anna-Lena, et al.
Publicado: (2014)

Juvenile arthritis disease activity score (JADAS) based on C-reactive protein predicts DMARD treatment in juvenile idiopathic arthritis in a Nordic multicenter cohort
por: Nordal, Ellen, et al.
Publicado: (2012)

Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction
por: Wojdas, Magdalena, et al.
Publicado: (2022)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Discontinuation of etanercept after clinical remission in patients with juvenile idiopathic arthritis
por: Cohen, Jean-David, et al.
Publicado: (2012)

The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
por: Livermore, P, et al.
Publicado: (2016)

Predictors of response to methotrexate in juvenile idiopathic arthritis
por: Albarouni, Mohamed, et al.
Publicado: (2014)

Methotrexate in oligoarticular persistent juvenile idiopathic arthritis
por: Horneff, Gerd, et al.
Publicado: (2014)

Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study
por: Ekelund, Maria, et al.
Publicado: (2017)

Ongoing disease-activity and change in ILAR categories in a Nordic juvenile idiopathic arthritis cohort
por: Nordal, Ellen, et al.
Publicado: (2012)

Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
por: Kahn, Robin, et al.
Publicado: (2016)

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
por: Verazza, Sara, et al.
Publicado: (2014)

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
por: Verazza, Sara, et al.
Publicado: (2016)

Transitioning patients with juvenile idiopathic arthritis to adult care: the Nordic experience
por: Mikola, Katriina, et al.
Publicado: (2022)

Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study
por: Nordal, Ellen, et al.
Publicado: (2017)

Experience of the concentration of methotrexate evaluation in children with juvenile idiopathic arthritis
por: Rokhlina, FV, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_362s5j7a6eoeglcbno0tk1rh5h